SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Hyperliquid is a layer one (L1) blockchain best known for perpetual futures and spot trading. Beyond its flagship DEX trading platform, the ecosystem supports borrowing, lending, real world assets (RWAs), and a full-fledged Ethereum Virtual Machine (EVM), making it a leading force in decentralized finance (defi).   Just as electronic trading dramatically improved markets in the 2000s, Hyperliquid offers an opportunity for a massive technical upgrade of the existing financial system through a transparent, efficient, and resilient blockchain. HYPE is the native token of the Hyperliquid blockchain, with a maximum supply of 1 billion.

Hype

HYPE is experiencing intense community interest as investors track its performance against major digital asset treasury models and watch for potential momentum breakouts. Traders are actively debating the token's infrastructure utility versus speculative price discovery, with significant focus on its open interest and integration into broader decentralized finance protocols.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is trending as the community rallies around its focus on global cannabis culture, positioning it as a movement-based crypto project rather than just a meme. Investors are actively discussing its potential for long-term utility in the cannabis industry, with many sharing persistent sentiment and organic growth strategies ahead of the 4/20 holiday.

Hyliion Holdings Corp. engages in the development of sustainable electricity-producing technology. It focuses on providing modular power plant technology that can operate on various fuel sources through the KARNO power module. The company was founded by Thomas J. Healy in 2015 and is headquartered in Cedar Park, TX.

Hyliion Holdings Corporation - Ordinary Shares - Class A

Hyliion Holdings Corp

Hyliion Holdings Corp is experiencing a significant surge in momentum driven by its pivot to the KARNO generator technology, which is being positioned as a key solution for AI data center power needs and military applications. The community is actively discussing the stock's recent UL certification, positive financial reports, and ongoing institutional interest, fueling speculation that the company is at an inflection point similar to other successful energy infrastructure plays.

Hyperliquid Strategies, Inc. is a holding and operating company, which engages in the business of crypto asset management. The firm operates as a digital asset treasury company which focuses on the Hyperliquid ecosystem. The company was founded on July 2, 2025 and is headquartered in New York, NY.

Hyperliquid Strategies Inc.

Hyperliquid Strategies Inc. ($PURR) is seeing a surge in investor attention and bullish sentiment, driven by its strategic exposure to the native HYPE token and positive momentum surrounding Hyperliquid's exchange growth. The community is actively discussing the stock's potential for significant upside as a 'proxy' for the HYPE ecosystem, though some participants remain focused on monitoring share issuance levels and the stock's performance relative to its underlying asset treasury.

Assertio Holdings, Inc. is a commercial pharmaceutical company, which engages in acquisitions, licensing, and mergers. The firm focuses on portfolio of neurology, inflammation, and pain medications. Its products include INDOCIN, Sympazan, Otrexup, SPRIX, CAMBIA, and Zipsor. The company was founded on August 7, 1995 and is headquartered in Lake Forest, IL.

Assertio Holdings Inc

Investors are closely monitoring Assertio Holdings as the company navigates a transition into a pure-play specialty pharmaceutical entity, with community sentiment driven by management's strategic focus on Rolvedon and Sympazan following the divestiture of legacy assets. Shareholders are actively debating the firm's valuation versus its significant cash position and potential for same-day dosing approvals, while concurrently navigating legal headwinds that have historically pressured the stock.

XRP is a decentralized digital asset and the native token of the XRP Ledger, a Layer 1 blockchain designed for high-performance global payments. Its primary value proposition is offering a fast, cost-effective alternative to traditional banking systems by enabling near-instant cross-border settlements that finalize in three to five seconds. By serving as a neutral bridge asset between different fiat currencies, it helps financial institutions lower liquidity costs and eliminates the need for pre-funded accounts.  The network is unique because it utilizes a federated consensus protocol instead of energy-intensive mining or staking. This system achieves deterministic finality through a Unique Node List of trusted validators who must reach an eighty percent agreement threshold to permanently record transactions. This infrastructure supports a sustained throughput of 1,500 transactions per second and includes a built-in decentralized exchange that allows for the automated trading of any tokenized asset without intermediaries.  The project traces its origins back to 2004 with Ryan Fugger before being co-founded in its modern form by Jed McCaleb and Chris Larsen. The company, now known as Ripple, works with major financial institutions as partners and investors to build global payment solutions. To protect the network from spam, a small amount of XRP is burned during every transaction, and the token is further utilized by institutions as collateral to access traditional markets and manage digital asset infrastructure.  Institutional adoption of the asset reached a major milestone in November 2025 when the SEC approved the first wave of spot XRP ETFs. These products, offered by major issuers including Bitwise, Grayscale, 21Shares, Canary Capital, and Franklin Templeton, are now listed on prominent exchanges like the NYSE Arca, Nasdaq, and Cboe BZX. While Ripple remains a key contributor to the ecosystem, the underlying XRP Ledger continues to operate as an open-source and decentralized network.

Ripple

The community remains deeply polarized over Ripples long-term potential, with debates fueled by anticipation for the CLARITY Act and conflicting reports on institutional adoption from major banks. While some investors view the recent price consolidation as a strategic accumulation phase, others are increasingly frustrated by prolonged stagnant performance and skepticism regarding regulatory timelines.

Chewy, Inc. operates as an online retailer of pet food and other pet-related products and services. It supplies pet medications, food, treats and other pet-health products and services for dogs, cats, fish, birds, small pets, horses, and reptiles. It has a portfolio of pet healthcare offerings that includes Chewy Pharmacy, Connect with a Vet, and CarePlus, an exclusive suite of pet-first insurance and wellness plans. The company was founded by Ryan Cohen and Michael Day in September 2011 and is headquartered in Plantation, FL.

Chewy Inc - Ordinary Shares - Class A

Chewy Inc

Chewy is trending as the stock hits new 52-week lows, fueling intense community debate over whether the current valuation represents a deep-value opportunity for long-term investors or the start of a further decline toward single digits. While bulls emphasize the resilience of the pet-care subscription model and call for management to initiate share buybacks, bears point to weakening consumer spending and a broader downward trend to argue that the stock remains caught in a bearish cycle.

Solana is a high-performance Layer 1 blockchain designed for mass adoption by providing a fast, secure, and low-cost environment for decentralized applications. It distinguishes itself by scaling globally without the use of complex sharding or multiple layers, instead maintaining a single, unified ledger to avoid liquidity fragmentation. This architecture allows it to process thousands of transactions per second with sub-second finality, often at a cost of less than a penny per transaction.  The network operates on a unique hybrid model that combines Proof of Stake with an innovation called Proof of History, which functions as a decentralized clock to timestamp transactions. This system reduces the need for constant node communication, allowing the Sealevel engine to run non-conflicting smart contracts in parallel across multiple CPU cores. Further efficiency is gained through the Gulf Stream protocol, which reduces confirmation times by forwarding transactions to validators before the current block is finished.  Founded in 2017 by Anatoly Yakovenko, Solana is now supported by the Switzerland-based Solana Foundation and significant institutional investors like Andreessen Horowitz and Polychain Capital. The platform’s native token, SOL, serves as the primary currency for paying transaction fees, participating in network governance, and securing the system through staking.   Solana has also seen significant institutional adoption ranging from spot Solana ETFs to major partnerships including Visa's 2025 launch of USDC settlement on the network and the tokenization of public equity by firms like Galaxy Digital.

Solana

Solana is generating significant community conversation as investors monitor regulatory developments like the CLARITY Act alongside activity in the meme coin ecosystem, particularly surrounding long-standing projects like UPDOG. While market participants debate the impact of broader economic trends and geopolitical instability, many remain focused on the network's high transaction throughput and long-term staking utility.

Chainlink is the industry-standard decentralized oracle network that solves the "oracle problem" by connecting smart contracts with real-world data. Blockchains cannot access external information on their own, so Chainlink acts as a secure bridge, enabling smart contracts to react to real-world events using verified, tamper-proof data. It is widely considered one of the first decentralized oracle networks and is the market leader in bringing off-chain data on-chain.  The platform operates through a decentralized network of nodes that fetch, validate, and deliver data to smart contracts. When a contract requests information like a stock price, a committee of independent nodes retrieves and aggregates the data to reach consensus, then delivers a single trustworthy answer. Chainlink offers a suite of services including Data Feeds for asset prices, CCIP for cross-chain token transfers and messaging, Automation for triggering smart contract functions, and Proof of Reserve for verifying asset collateralization.  Chainlink has established itself as critical infrastructure for both DeFi and institutional adoption, with partnerships including Swift, Euroclear, Mastercard, UBS, ANZ, Fidelity International, and J.P. Morgan. Its institutional products include the Chainlink Runtime Environment for tokenized asset workflows, Confidential Compute for privacy-preserving computation, and the Automated Compliance Engine for embedding regulatory rules into smart contracts.  The LINK token is the native asset used to pay node operators for services, fund subscription accounts, and incentivize network security through staking. Node operators stake LINK as collateral, which can be slashed if they provide inaccurate data. Chainlink was co-founded in 2017 by Sergey Nazarov and Steve Ellis, who co-authored the white paper with Ari Juels, and raised $32 million in its September 2017 ICO.

ChainLink

ChainLink is trending as investors debate its role as a fundamental infrastructure layer for RWA tokenization and cross-chain messaging, despite recent bearish price action. Community sentiment is sharply divided between long-term holders accumulating at lower price levels and frustrated traders expressing skepticism over its stagnant valuation compared to other assets.

SPDR Series Trust - State Street SPDR S&P Biotech ETF

SPDR S&P Biotech ETF

The SPDR S&P Biotech ETF is currently garnering significant attention as investors monitor a surge in M&A activity alongside anticipation for clinical data readouts ahead of major upcoming medical conferences. Community sentiment remains focused on identifying undervalued commercial-stage names, with active debate centered on separating companies with genuine long-term clinical potential from those facing binary risk or speculative hype.

statis crypto Watchlist

Bitcoin

Ethereum

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Insider Buying: Nuvilex (NASDAQ:PMCB) Director Acquires 20,000 Shares of Stock

Nuvilex Inc. (NASDAQ:PMCB - Get Free Report) Director Jonathan Schechter purchased 20,000 shares of Nuvilex stock in a transaction that occurred on Monday, January 5th. The shares were bought at an...

PMCB Stock Jumps 25% After Company Sells Stake In Femasys

Equity

PharmaCyte noted that it now has approximately $25 million in marketable securities, in addition to roughly $20 million in cash.


PharmaCyte Biotech, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatments for cancer and diabetes. It focuses on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box, which will be used as a platform for the development of treatments for inoperable pancreatic cancer and other solid cancerous tumors, and diabetes. The company was founded on October 28, 1996 and is headquartered in Las Vegas, NV.

PMCB
PharmaCyte Biotech Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Compact View

Poll

Latest PMCB News

PMCBPharmaCyte Biotech Inc